Dov A. Goldstein MD - 13 Jan 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Financial Officer
Signature
/s/ Dov A. Goldstein
Issuer symbol
BIOA
Transactions as of
13 Jan 2026
Net transactions value
-$305,298
Form type
4
Filing time
15 Jan 2026, 16:22:20 UTC
Previous filing
06 Jan 2026
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOLDSTEIN DOV A MD Chief Financial Officer C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE /s/ Dov A. Goldstein 15 Jan 2026 0001120478

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIOA Common Stock Options Exercise $226,530 +27,000 +120% $8.39 49,408 13 Jan 2026 Direct F1
transaction BIOA Common Stock Sale $165,371 -8,974 -18% $18.43 40,434 13 Jan 2026 Direct F1, F2
transaction BIOA Common Stock Sale $86,370 -4,440 -11% $19.45 35,994 13 Jan 2026 Direct F1, F3
transaction BIOA Common Stock Sale $239,549 -11,663 -32% $20.54 24,331 13 Jan 2026 Direct F1, F4
transaction BIOA Common Stock Sale $40,538 -1,923 -7.9% $21.08 22,408 13 Jan 2026 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Options Exercise $0 -27,000 -23% $0.000000 92,587 13 Jan 2026 Common Stock 27,000 $8.39 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive.
F6 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.